Adjuvant Pembrolizumab in Resected Stage IIB or IIC Melanoma

Source: The ASCO Post, April 2022

As reported in The Lancet by Luke et al, the phase III KEYNOTE-716 trial has shown significantly prolonged recurrence-free survival with adjuvant pembrolizumab vs placebo in patients with high-risk completely resected stage IIB/IIC melanoma at both first and second interim analyses.

The first interim analysis of the trial supported the December 2021 approval of pembrolizumab as adjuvant treatment of adult and pediatric (? 12 years of age) patients with stage IIB or IIC melanoma following complete resection.

READ THE ORIGINAL FULL ARTICLE